The factor structure of extrapyramidal symptoms evaluated using the Drug‐Induced Extrapyramidal Symptoms Scale in patients with schizophrenia: Results from the 2016 REAP AP‐4 study. (3rd December 2022)

• Record Type: Journal Article
• Authors: Kubota, Chika; Inada, Toshiya; Lin, Shih‐Ku; Avasthi, Ajit; Chee, Kok Yoon; Tanra, Andi Jayalangkara; Yang, Shu‐Yu; Chen, Lian‐Yu; Chong, Mian‐Yoon; Tripathi, Adarsh; Kallivayalil, Roy Abraham; Grover, Sandeep; Park, Seon‐Cheol; Kato, Takahiro A.; Xiang, Yu‐Tao; Sim, Kang; Maramis, Margarita M.; Noor, Isa Multazam; Tan, Chay‐Hoon; Sartorius, Norman; Shinfuku, Naotaka
• Is Part Of: Human psychopharmacology. Volume 38:Number 2(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-12-03
• Subjects: antipsychotics -- DIEPSS -- extrapyramidal symptoms -- schizophrenia; Psychopharmacology -- Periodicals; Psychotropic drugs -- Periodicals; Psychopharmacology -- Periodicals; Psychotropic Drugs -- pharmacology -- Periodicals; 615.78
• DOI: 10.1002/hup.2861
• Languages: English
• ISSNs: 0885-6222

Abstract

Abstract: Introduction: Drug‐induced extrapyramidal syndrome (EPS) remains a major problem in clinical psychiatry. This study aimed to examine the factor structure of drug‐induced extrapyramidal symptoms observed in patients with schizophrenia and assessed using the Drug‐Induced Extrapyramidal Symptoms Scale (DIEPSS). Methods: The participants were 1478 patients with a diagnosis of schizophrenia whose EPS was assessed using the DIEPSS in India, Indonesia, Japan, Malaysia, and Taiwan in the 2016 REAP AP‐4 study. The records of the participants were randomly divided into two subgroups: the first for exploratory factor analysis of the eight DIEPSS items, and the second for confirmatory factor analysis. Results: The factor analysis identified three factors: F1 (gait and bradykinesia), F2 (muscle rigidity and tremor), and F3 (sialorrhea, akathisia, dystonia, and dyskinesia). Conclusion: The results suggest that the eight individual items of the DIEPSS could be composed of three different mechanisms: acute parkinsonism observed during action (F1), acute parkinsonism observed at rest (F2), and central dopaminergic mechanisms with pathophysiology other than acute parkinsonism (F3).